Cargando…

Assessment of Effective Anti-TB Regimens and Adverse Outcomes Related Risk Factors in the Elderly and Senile-Aged TB Patients

OBJECTIVE: Compared to younger patients with tuberculosis (TB), elderly and senile-aged patients with TB had a higher incidence of adverse outcomes particularly in terms of lost to follow-up and deaths. Our study aimed to gain insight into the effectiveness of anti-tuberculosis (anti-TB) treatment i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Jing, Liu, Zhong-Da, Feng, Yin-Ping, Luo, Shui-Rong, Jiang, Qiao-Min
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10289104/ https://www.ncbi.nlm.nih.gov/pubmed/37361933 http://dx.doi.org/10.2147/IDR.S414918

Ejemplares similares

Is intermittent short-course anti-TB regimen as efficient and safe as daily anti-TB regimen for treating childhood TB?
por: Bhaumik, Soumyadeep
Publicado: (2015)

The Cost-Effectiveness of the BEAT-TB Regimen for Pre-Extensively Drug-Resistant TB
por: Muniyandi, Malaisamy, et al.
Publicado: (2023)

UNITE4TB: a new consortium for clinical drug and regimen development for TB
por: Boeree, M. J., et al.
Publicado: (2021)

The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens
por: Khan, Uzma, et al.
Publicado: (2019)

Cost-effectiveness of new MDR-TB regimens: study protocol for the TB-PRACTECAL economic evaluation substudy
por: Sweeney, Sedona, et al.
Publicado: (2020)

Refining MDR-TB treatment regimens for ultra short therapy (TB-TRUST): study protocol for a randomized controlled trial
por: Weng, Taoping, et al.
Publicado: (2021)

Confronting TB/HIV in the era of increasing anti-TB drug resistance
por: Chakaya, Jeremiah, et al.
Publicado: (2008)

Shorter TB treatment regimens should be safer as well
por: Rucsineanu, O., et al.
Publicado: (2023)

Adverse Events among HIV/MDR-TB Co-Infected Patients Receiving Antiretroviral and Second Line Anti-TB Treatment in Mumbai, India
por: Isaakidis, Petros, et al.
Publicado: (2012)

TB Anywhere is TB Everywhere
por: Wortham, Jonathan M.
Publicado: (2018)

TB or not TB! That’s the question
por: Nugud, Ahmed, et al.
Publicado: (2019)

Challenges of diabetes in elderly TB patients
por: Jali, M.V., et al.
Publicado: (2022)

Atripla(R)/anti-TB combination in TB/HIV patients. Drug in focus
por: Semvua, Hadija H, et al.
Publicado: (2011)

Effect of Gender on Clinical Presentation of Tuberculosis (TB) and Age-Specific Risk of TB, and TB-Human Immunodeficiency Virus Coinfection
por: Humayun, Maheen, et al.
Publicado: (2022)

Case Report: Kanamycin Ototoxicity and MDR-TB Treatment Regimen
por: Mantefardo, Bahru, et al.
Publicado: (2021)

191. High-Dose Rifampin-containing Regimens for the Treatment of TB Meningitis
por: Ruiz-Bedoya, Camilo A, et al.
Publicado: (2021)

Investigating Non-sterilizing Cure in TB Patients at the End of Successful Anti-TB Therapy
por: Beltran, Caroline G. G., et al.
Publicado: (2020)

Can Pan-TB shorter regimens be a promising hope for ending TB in India by 2025 in ongoing COVID-19 era?
por: Prasad, Rajendra, et al.
Publicado: (2022)

Striking the Right Balance Determines TB or Not TB
por: BoseDasgupta, Somdeb, et al.
Publicado: (2014)

Use of Anti-Retroviral Therapy in Tuberculosis Patients on Second-Line Anti-TB Regimens: A Systematic Review
por: Arentz, Matthew, et al.
Publicado: (2012)

P25 TB or not TB? An unusual case of inflammatory arthritis in an anti-CCP positive patient
por: Al-Attar, Mariam, et al.
Publicado: (2023)

How Do Patients Who Fail First-Line TB Treatment but Who Are Not Placed on an MDR-TB Regimen Fare in South India?
por: Burugina Nagaraja, Sharath, et al.
Publicado: (2011)

Prognostic factors among TB and TB/DM comorbidity among patients on short course regimen within Nairobi and Kiambu counties in Kenya
por: Mburu, Josephine W., et al.
Publicado: (2018)

Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort( )
por: Hewison, Catherine, et al.
Publicado: (2022)

Multidrug-Resistant TB (MDR-TB) and Extensively Drug-Resistant TB (XDR-TB) Among Children: Where We Stand Now
por: Chowdhury, Kona, et al.
Publicado: (2023)

Adverse Events in Healthy Individuals and MDR-TB Contacts Treated with Anti-Tuberculosis Drugs Potentially Effective for Preventing Development of MDR-TB: A Systematic Review
por: Langendam, Miranda W., et al.
Publicado: (2013)

A longitudinal study on latent TB infection screening and its association with TB incidence in HIV patients
por: Wong, Ngai Sze, et al.
Publicado: (2019)

Comparison of the Sensitivity of QuantiFERON-TB Gold In-Tube and T-SPOT.TB According to Patient Age
por: Bae, Won, et al.
Publicado: (2016)

Accelerating development of new shorter TB treatment regimens in anticipation of a resurgence of multi-drug resistant TB due to the COVID-19 pandemic
por: Tiberi, Simon, et al.
Publicado: (2021)

Assessment of Anti-TB Drug Nonadherence and Associated Factors among TB Patients Attending TB Clinics in Arba Minch Governmental Health Institutions, Southern Ethiopia
por: Gube, Addisu Alemayehu, et al.
Publicado: (2018)

Coordinated In Vitro Release of Granulysin, Perforin and IFN-γ in TB and HIV/TB Co-Infection Associated with Clinical Outcomes before and after Anti-TB Treatment
por: Pitabut, Nada, et al.
Publicado: (2020)

Clinical standards for the management of adverse effects during treatment for TB
por: Singh, K. P., et al.
Publicado: (2023)

XDR-TB in South Africa: Back to TB Sanatoria Perhaps?
por: Sakoane, Ramalitse
Publicado: (2007)

High prevalence of TB disease in contacts of adults with extrapulmonary TB
por: Wingfield, Tom, et al.
Publicado: (2018)

Investigation of the efficacy of the short regimen for rifampicin-resistant TB from the STREAM trial
por: Phillips, P. P. J., et al.
Publicado: (2020)

Implementing the 4R and 9H regimens for TB preventive treatment in Indonesia
por: Apriani, L., et al.
Publicado: (2022)

Correction to: Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort
Publicado: (2023)

Assessing the impact of TB/HIV services integration on TB treatment outcomes and their relevance in TB/HIV monitoring in Ghana
por: Ansa, Gloria Akosua, et al.
Publicado: (2012)

Addressing TB multimorbidity in policy and practice: An exploratory survey of TB providers in 27 high-TB burden countries
por: Jarde, Alexander, et al.
Publicado: (2022)

Heterogenous Immune Response to TB is Not a False Negative
por: Wang, Mao-Shui, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_63q9bafes4g7o78n4gtv0r10l0